Companion Diagnostics Market by Indication (Cardiovascular Disease, Breast, Lung & Colorectal Cancer), Product & Service (Software & Service, Assay, Kit), Technology (ISH, PCR, NGS, IHC), End-User (Pharma Companies, CRO), Region – 2021 to 2026

$3,850.00$5,850.00

Published on: July 24, 2021
Clear
SKU: GMS-2105 Category:

OVERVIEW

The global diagnostic companion market is projected to hit USD 7.78 billion by 2025, rising over the forecast period at a CAGR of 13.34%. The advantages of companion diagnostics, the the need for targeted treatment, the the importance of personalized medicine, the the global incidence of cancer and the ever-rising application areas of companion diagnostics drive the growth of the global companion diagnostics industry.

Companion Diagnostics Market by Indication (Cardiovascular Disease, Breast, Lung & Colorectal Cancer), Product & Service (Software & Service, Assay, Kit), Technology (ISH, PCR, NGS, IHC), End-User (Pharma Companies, CRO), Region - 2021 to 2026 1

Companion Diagnostics Market by Indication (Cardiovascular Disease, Breast, Lung & Colorectal Cancer), Product & Service (Software & Service, Assay, Kit), Technology (ISH, PCR, NGS, IHC), End-User (Pharma Companies, CRO), Region - 2021 to 2026 2

Companion Diagnostics Market by Indication (Cardiovascular Disease, Breast, Lung & Colorectal Cancer), Product & Service (Software & Service, Assay, Kit), Technology (ISH, PCR, NGS, IHC), End-User (Pharma Companies, CRO), Region - 2021 to 2026 3

Companion Diagnostics Market by Indication (Cardiovascular Disease, Breast, Lung & Colorectal Cancer), Product & Service (Software & Service, Assay, Kit), Technology (ISH, PCR, NGS, IHC), End-User (Pharma Companies, CRO), Region - 2021 to 2026 4

Companion Diagnostics Market by Indication (Cardiovascular Disease, Breast, Lung & Colorectal Cancer), Product & Service (Software & Service, Assay, Kit), Technology (ISH, PCR, NGS, IHC), End-User (Pharma Companies, CRO), Region - 2021 to 2026 5

Companion Diagnostics Market by Indication (Cardiovascular Disease, Breast, Lung & Colorectal Cancer), Product & Service (Software & Service, Assay, Kit), Technology (ISH, PCR, NGS, IHC), End-User (Pharma Companies, CRO), Region - 2021 to 2026 6

Companion Diagnostics Market by Indication (Cardiovascular Disease, Breast, Lung & Colorectal Cancer), Product & Service (Software & Service, Assay, Kit), Technology (ISH, PCR, NGS, IHC), End-User (Pharma Companies, CRO), Region - 2021 to 2026 7

Companion Diagnostics Market by Indication (Cardiovascular Disease, Breast, Lung & Colorectal Cancer), Product & Service (Software & Service, Assay, Kit), Technology (ISH, PCR, NGS, IHC), End-User (Pharma Companies, CRO), Region - 2021 to 2026 8

TABLE OF CONTENT

1 Global Companion Diagnostics Market – Overview
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries

2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Global Companion Diagnostics Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography
3.4 Top 5 Financials Analysis
4 Global Companion Diagnostics Market – Market Forces
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Challenges
4.3 Porters Analysis of Market

4.3.1 Bargaining power of suppliers
4.3.2 Bargaining powers of customers
4.3.3 Threat of new entrants
4.3.4 Rivalry among existing players
4.3.5 Threat of substitutes
5 Global Companion Diagnostics Market – By Product & Service (Market Size – &
million/billion)
5.1 Assay kits & Reagents
5.2 Software & Services
6 Global Companion Diagnostics Market – By Technology
6.1 Polymerase Chain Reaction (PCR)
6.2 In Situ Hybridization (ISH)
6.3 Next-Generation Sequencing (NGS)
6.4 Immunohistochemistry (IHC)
6.5 Others
7 Global Companion Diagnostics Market – By Indication
7.1 Cardiovascular
7.2 Neurological Diseases
7.3 Cancer
7.4 Infectious Diseases
7.5 Others
8 Global Companion Diagnostics Market – By End-User
8.1 Pharmaceutical & Biopharmaceutical Companies
8.2 Reference Laboratories
8.3 CROs
8.4 Others
9 Global Companion Diagnostics Market – By Geography (Market Size – & million/billion)
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 U.K

9.3.2 Germany
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 South Korea
9.4.5 Rest of APAC
9.5 Rest of the World
9.5.1 South America
9.5.2 Middle East
9.5.3 Africa
10 Global Companion Diagnostics Market – Entropy
10.1 New product launches
10.2 M&A's, collaborations, JVs and partnerships
11 Global Companion Diagnostics Market Company Profile (Key Players)
11.1 Market Share, Company Revenue, Products, M&A, Developments
11.2 F. Hoffmann-La Roche AG
11.3 Agilent Technologies, Inc.
11.4 QIAGEN N.V.
11.5 Danaher Corporation
11.6 Abbott Laboratories, Inc.
11.7 Biomérieux SA
11.8 Myriad Genetics, Inc.
11.9 Sysmex Corporation
11.10 Almac Group
11.11 Illumina Inc.
11.12 Company 11 & more
12 Global Companion Diagnostics Market – Appendix
12.1 Sources

12.2 Abbreviations